The invention is directed to compositions and methods comprising nicotinicagonists for treating e.g., nervous systemdisorders, in particular, to combination therapies that include a nicotinicagonist (for example, nicotine) and a nicotinic acetylcholinereceptor desensitization inhibitor (for example, opipramol).